Document Detail


Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension.
MedLine Citation:
PMID:  2475687     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of verapamil, a calcium channel blocker in slow-release form, 240 mg once a day, was assessed in 1,412 ambulatory, mildly to moderately hypertensive patients. Blood pressure decreased from 171.82 +/- 17/103.55 +/- 6 mm Hg at week 0 to 157 +/- 15/93.6 +/- 8 mm Hg at 2 weeks (p less than 0.001) in 78% of patients. At week 12 there were 1,249 patients (88%) controlled with therapy, either with verapamil alone (950 patients, 67%) or plus additional diuretic (21%). Blood pressure showed a mean decrease of 24.6 mm Hg in systolic and 17.2 mm Hg in diastolic pressure at week 12. Heart rate decreased from 81.4 +/- 11 beats/min at week 0 to 75.69 +/- 8.5 beats/min at week 12 (p less than 0.05). There were no statistical differences in the effect on diastolic blood pressure between elderly (greater than 65 years) and nonelderly patients in the study, although the elderly showed higher baseline systolic pressure (178.27 +/- 17 mm Hg vs. 168.97 +/- 16 mm Hg, p less than 0.001) than did nonelderly patients. Verapamil therapy produced a similar effect on systolic pressure (p = NS) in younger patients (23.96 mm Hg decrement) and in the elderly (25.93 mm Hg decrement). The overall incidence of adverse reactions was 16.58%, accounting for 1.06% of patients' withdrawals. Constipation (5%) was the most common side effect. We conclude that slow-release verapamil, 240 mg once a day, is an effective therapeutic alternative in systemic hypertension, and must be included in the first step of antihypertensive therapy.
Authors:
C Gómez Pajuelo; J Pérez Naranjo; I Ruiz Martínez
Related Documents :
2662047 - Effects of nitrendipine on blood pressure and blood ciclosporin a level in patients wit...
24970557 - Development of a high-performance anesthesia ventilator for research in small animals.
9218667 - Prevention of heart failure by antihypertensive drug treatment in older persons with is...
2046107 - Prevention of stroke by antihypertensive drug treatment in older persons with isolated ...
16739867 - Observations on peripheral microcirculation in young hypertensive patients.
35917 - Effect of non-carbonic acidosis on total splanchnic perfusion and cardiac output during...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  13 Suppl 4     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1989  
Date Detail:
Created Date:  1989-09-22     Completed Date:  1989-09-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S50-2     Citation Subset:  IM    
Affiliation:
Servicio de Cardiología, Hospital 1 de Octubre, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aging / physiology
Blood Pressure / drug effects
Delayed-Action Preparations
Female
Heart Rate / drug effects
Humans
Hypertension / drug therapy*,  physiopathology
Male
Middle Aged
Outpatients
Sex Factors
Verapamil / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phas...
Next Document:  Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic pati...